Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Tafamidis 12.2 mg Tablet Formulations
NCT05482308Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tafamidis in transthyretin amyloidosis (ATTR) (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Plasma Concentration-time Profile From Time Zero Extrapolated to Infinite Time and Maximum Plasma Concentration. Started Aug 2022; status: completed.
02
Drugs
tafamidis
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT05482308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05482308.